InvestorsHub Logo
Followers 6
Posts 606
Boards Moderated 0
Alias Born 09/22/2018

Re: None

Tuesday, 12/18/2018 10:11:54 PM

Tuesday, December 18, 2018 10:11:54 PM

Post# of 54907
Unfortunately,

The current price action is the company's fault. They know what needs to be done, but simply do not care about shareholder value. It's as if some bean counter in the back office is running the place.

In their 12/04/18 investment profile they announce they are cashflow positive with no debt. What about stock costs????? Their quarterly and annual filings are unreadable, because of the overwhelming amount of stock, options, warrants, etc.......

Their news releases are poorly written and don't seem to tell the story that has been presented in other formats - like investor conferences, etc. Crap, the endo test kit news release was one of the poorest news announcements ever??? Nobody, including myself, understood whether or a not a pilot test kit was being announced, or the formal Endometriosis test kit we've been hearing about for over a year. (people still don't know - because the company hasn't actually told us!!!) The investment collateral states this test kit alone has the potential in Year 1 of $150 million in revenue.......why wasn't something like that in the news release? Then the FORM 10 states that they pay Juneau 50% of the net profit??? What is that all about, they gave them a boat load of stock and still have to split it 50/50......just doesn't make any sense.

Has the company shipped any endo test kits? Wouldn't that be a nice news release.......considering the stem cell growth from Q4 to Q1 has stalled at 10% growth, we need the next catalyst, the next good thing.

Hopeful and waiting for them to establish some consistent business execution.........I am long the stock, but feeling discouraged....